Risperidone half-life in a patient taking paroxetine -- a case report

Area of Science:

• Pharmacology
• Clinical Pharmacy

Background:

• Risperidone is an antipsychotic medication metabolized in the liver.
• Paroxetine is a selective serotonin reuptake inhibitor (SSRI) known to inhibit certain cytochrome P450 enzymes.
• Drug-drug interactions can alter the metabolism and efficacy of antipsychotics.

Observation:

• A patient experiencing side effects discontinued risperidone.
• Blood levels of risperidone and its active metabolite 9-hydroxyrisperidone were monitored.
• Significant decreases in risperidone and 9-hydroxyrisperidone levels were observed post-discontinuation.

Findings:

• The estimated half-lives of risperidone, 9-hydroxyrisperidone, and the total moiety were calculated.
• The pharmacokinetic data suggest a significant drug interaction, likely due to paroxetine's inhibitory effect on risperidone metabolism.
• Baseline risperidone levels were 33 ng/ml, decreasing to 4 ng/ml after discontinuation.

Implications:

• Clinicians should consider potential interactions between paroxetine and risperidone.
• Monitoring drug levels may be necessary in patients taking both medications.
• Understanding these interactions is crucial for optimizing antipsychotic therapy and minimizing adverse events.